Updated Data Show Targeted Drug Ibtrozi Can Keep ROS1-Positive Lung Cancer Under Control For Longer
SHARE

Fact Checked

SurvivorNet Fact Checking and Medical Review Standards:  

The SurvivorNet News Team creates high quality medical information that complies with our industry leading standards for factual accuracy and sourcing from leading experts at academic medical institutions. Every news article is thoroughly fact-checked by our physician collaborators. We vet each piece of work for factual integrity, impartiality, and clearly label any professional conflicts.

All SurvivorNet articles adhere to the following standards:

  1. All studies and research papers cited are from reputable academic medical institutions or peer-reviewed journals.
  2. When we use data, statistics, or quotes these references link to the original source.
  3. All content related to new treatments, drugs, procedures, and so on must clearly describe availability, side effects, treatment target (such as triple negative breast cancer)
  4. All medical information on SurvivorNet is sourced from respected medical professionals with verified medical credentials and links are provided to these sources.
  5. We strive to give the reader relevant background information and include, clearly-sourced contextual health information in all articles. Readers are clearly alerted to any conflicts of interest from a medical source or the authors of a cited study.
/ Published Sep 21, 2026

Updated Data Show Targeted Drug Ibtrozi Can Keep ROS1-Positive Lung Cancer Under Control For Longer

Medical Source: Dr. Kaique Filardi
University of São Paulo

What To Know About TKI Inhibitor Taletrectinib (Ibtrozi)

  • The Food and Drug Administration approved an update to the label for a targeted drug called taletrectinib (brand name: Ibtrozi) after trial data showed it helped keep a subtype of lung cancer controlled for an average of more than 4 years.
  • The drug, a tyrosine kinase inhibitor (TKI), is approved for patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). The updated duration of response data comes from patients who had not been treated with another ROS1-targeted drug.
  • Doctors say it’s a highly effective option with fewer nerve‑related side effects than similar drugs, offering patients a real chance at long‑lasting stability.
  • “The side effect profile of taletrectinib suggests that the drug is well tolerated by patients and side effects can be easily managed by dose reduction and interruption,” Dr. Angel Qin, a medical oncologist at University of Michigan Health, tells SurvivorNet.
  • The approved population has not changed. Patients should discuss ROS1 testing, brain metastases, other targeted drugs, and side effects with their doctor.
The U.S. Food and Drug Administration (FDA) has updated the label for taletrectinib (brand name: Ibtrozi), an oral targeted treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has a specific classification known as ROS1-positive. New data show that the drug can lead to even longer responses.

This is not the drug’s first approval or a new indication. Taletrectinib was approved in June 2025 for adults whose cancer has spread within the chest or elsewhere. The September 2026 action adds longer follow-up from the same studies, clarifying how long tumor responses lasted.

Read More
Non-small cell lung cancer is the most common type of lung cancer. A small percentage of these tumors have a ROS1 fusion, in which ROS1, a gene, becomes joined to another gene. This creates an abnormal signal that tells cancer cells to grow. Tumor testing, and sometimes blood testing, can find the feature.

“The approval of taletrectinib represents an important advance for patients with ROS1-positive lung cancer,” Dr. Vamsi Velcheti, chief of hematology and oncology at Mayo Clinic in Jacksonville, Florida, tells SurvivorNet. “It is encouraging to see durability of benefit — with responses lasting a median of more than four years in previously untreated patients — along with meaningful activity in patients whose cancer has progressed on prior ROS1-targeted therapy.”

WATCH: How Does Molecular Testing Help Determine the Best Lung Cancer Treatment Option?

“For patients diagnosed with this uncommon form of lung cancer, this provides another highly effective targeted treatment option and real hope for achieving prolonged disease control while living well with their cancer,” Dr. Velcheti adds.

Taletrectinib is a tyrosine kinase inhibitor (TKI), a medicine that blocks the abnormal ROS1 signal. Unlike traditional chemotherapy, which acts more broadly against rapidly dividing cells, it targets this specific driver.

Other ROS1-targeted pills include crizotinib, entrectinib, and repotrectinib. The drugs differ in side effects and activity.

New Data Show Impressive Duration of Response

The main new number comes from 103 patients in the phase 2 TRUST-I study who had not received a ROS1 tyrosine kinase inhibitor. This is called ROS1 treatment-naive. Some patients had received chemotherapy.

The objective response rate was 90%. That means scans showed that the tumors became smaller or disappeared in 90 out of every 100 patients. A response is not a cure or proof that patients live longer, and cancer can later grow again.

Among 93 responders, the median duration of response was 49.7 months, more than four years. Half lasted longer and half less. The figure cannot predict one person’s result.

Dr. Angel Qin, a medical oncologist at University of Michigan Health, calls taletrectinib an “exciting new treatment option for patients with advanced/metastatic ROS1-positive NSCLC.”

“More importantly, taletrectinib is approved for use in patients who are treatment-naïve, meaning that it can be used prior to chemotherapy,” Dr. Qin adds.

Expert Resources for Lung Cancer Patients

The studies also found activity in brain metastases, or tumors that have spread to the brain. Those groups were small, so an individual response is not guaranteed.

In addition to the drug reducing cancer burden for most patients in a durable way, Dr. Qin explains, it also has a manageable side effect profile.

“The side effect profile of taletrectinib suggests that the drug is well tolerated by patients and side effects can be easily managed by dose reduction and interruption, with very few patients needing to stop the drug due to tolerability issues,” Dr. Qin says.

WATCH: Mutations That Matter in Lung Cancer and the Treatments Available for Them

The trials did not randomly compare taletrectinib with another ROS1 drug, so the results do not prove it is better than crizotinib, entrectinib, or repotrectinib.

Common side effects include:

  • Diarrhea
  • Nausea
  • Vomiting
  • Dizziness
  • Rash
  • Constipation
  • Fatigue

Serious risks include liver injury, lung inflammation, and heart-rhythm changes. For patients, blood tests and heart monitoring may be needed.

In the study, 7% of patients stopped treatment because of side effects, while others could manage effects by temporarily pausing treatment or adjusting their doses.

Questions To Ask Your Doctor

  • Has my tumor been tested for a ROS1 fusion?
  • Would taletrectinib be an option for me now or after another treatment?
  • How does taletrectinib compare with other ROS1-targeted drugs in my situation?
  • Does cancer in my brain affect which treatment you recommend?
  • What side effects and monitoring should I expect?

Learn more about SurvivorNet's rigorous medical review process.

Dr. Kaique Filardi is a board-certified general surgeon and gastrointestinal (GI) surgeon from the University of São Paulo. Read More

Late Stage Lung Cancer

Late stage lung cancer means that the disease has spread to other organs. The goal in these cases is to treat the whole body, destroying all the cancer cells. There are several options for how to approach treating stage four lung cancers.

NOW
PLAYING
How Is Treatment For Small Cell Lung Cancer Changing? The Era Of Immunotherapy
NOW
PLAYING
From New Treatment Combinations To Emerging Immunotherapies, A New Wave Of Treatments Are Providing Hope For Small Cell Lung Cancer
NOW
PLAYING
What To Expect When Taking Groundbreaking Targeted Therapy Osimertinib [Tagrisso] For Lung Cancer
NOW
PLAYING
The Importance Of Genetics In Lung Cancers
NOW
PLAYING
Targeted Therapy for Lung Cancer
NOW
PLAYING
Mom Who Mistakes Symptoms for Stress Is Diagnosed With Stage 4 Lung Cancer

My Health Questions

Powered by SurvivorNet

Rapid evidence support for real-world oncology decisions.

Not sure where to start? Try these questions.

icon

Can you help me find clinical trials for Lung Cancer?

icon

How do I know whether my lung cancer has a ROS1 fusion and needs testing?

icon

Could taletrectinib be used as my first treatment or only after another ROS1-targeted drug?

icon

What side effects and monitoring should I expect if I take taletrectinib?

Patient Pathfinder:

Clinical Trial Finder

Are you looking for other treatment options?
Right now there are ... lung cancer trials recruiting in the U.S. within 100 miles of

Enter your zip code and travel distance to explore trials in your area...

Continue The Journey

Explore: Later Stage Treatment

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider